FDA Approves Abbott's Next-Generation Stent

Before you go, we thought you'd like these...
Before you go close icon

Abbott Labsannounced in a press release late last week  that the Food and Drug Administration has approved the company's next-generation Xience Xpedition drug-eluting coronary stent.

The company is planning  for an immediate launch of the Xpedition with the approval in hand. The product gained CE Mark approval in Europe several months ago, and Abbott relied on similar data that won that recognition -- data compiled from 100 studies and thousands of patients -- to gain the FDA thumbs up.

Abbott's executive vice president of Medical Devices, Dr. John Capek, explained  the Xpedition's role in the company's future in the release, saying:

The launch of XIENCE Xpedition in the United States will advance Abbott's worldwide market-leading position in drug eluting stents. ... With its redesigned stent delivery system and a full matrix of sizes, XIENCE Xpedition provides physicians with a comprehensive, trusted option to treat a broad range of patients with coronary artery disease.


The approval marks the first  regulatory victory for Abbott since the company completed the spinoff of its pharmaceuticals business on Jan. 1.

The article FDA Approves Abbott's Next-Generation Stent originally appeared on Fool.com.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners